ELAVL2 and glioblastoma: To confirm the low expression level of ELAVL2 in GBM cell lines, we assessed the mRNA expression levels of ELAVL2 in various cancer cell lines, including GBM (T98G, U87MG, U373MG, and U251MG), hepatocellular carcinoma (HepG2), pancreatic cancer (Capan2), and colorectal adenocarcinoma (SNU407, HCT8, HCT15, SW480, and SW620).